Shelf life (days): 730.0
Formulation: A solution in methyl acetate
Formal Name: 9a,11a,15R-trihydroxy-17-phenyl-18,19,20-trinor-prost-5Z-en-1-oic-3,3',4,4'-d4 acid, isopropyl ester
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C26H36D4O5
Formula Weight: 436.6
Notes: Latanoprost-d4 is intended for use as an internal standard for the quantification of latanoprost (Item No. 16812) by GC- or LC-MS. Latanoprost is a derivative of prostaglandin F2α (PGF2α; Item Nos. 16010 / 16020), an FP receptor agonist, and a prodrug of latanoprost (free acid) (Item No. 16811).{11931} It induces phosphoinositide turnover in isolated human ciliary muscle and human trabecular meshwork cells, HEK293 cells expressing human ocular FP receptors, mouse NIH3T3 fibroblasts, and rat A7r5 vascular smooth muscle cells (EC50s = 313, 564, 173, 142, and 110 nM, respectively). Topical ocular application of latanoprost (0.005% twice per day) reduces intraocular pressure (IOP), without affecting outflow facility or aqueous humor flow rates, in cynomolgus monkeys in a model of laser-induced glaucoma.{51435} Formulations containing latanoprost have been used in the treatment of open-angle glaucoma or ocular hypertension.
English
Deutsch
